Tryton Medical Obtains $20,000,000 Series D Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7cc371ca-a6bc-4e1e-a69f-5a7dbb20258b&Preview=1 -
Date
9/14/2010 -
Company Name
Tryton Medical -
Mailing Address
1000 Park Forty Plaza Durham, MA 27713 -
Company Description
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery. -
Website
http://www.trytonmedical.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Series D -
Proceeds Purposes
This Series D financing enables us to conduct our U.S. pivotal trial and drive product adoption internationally. -
M&A Terms
-
Venture Investor
Arnerich Messina & Associates, Inc. -
Venture Investor
PTV Sciences -
Venture Investor
Spray Venture Partners -
Venture Investor
Rivervest Venture Partners
